OncoDNA:YourOncologyLabPortalforhealthcare

GoogleAnalyticssnippetaddedbySiteKit

EndGoogleAnalyticssnippetaddedbySiteKit

GoogleTagManagersnippetaddedbySiteKit

End Google Tag Manager snippet added by Site Kit 

 Google Tag Manager (noscript) snippet added by Site Kit 

 End Google Tag Manager (noscript) snippet added by Site Kit 

Solutions

Solid Biopsy (OncoDEEP® Kit)Liquid Biopsy (OncoSELECT® Kit)Molecular Residual Disease (MRD)OncoCDI – Clinical Data Intelligence 

Clinical TestingPrecision enrollmentMRD for PharmaKnowledge-driven medicineClinical Data Intelligence (OncoCDI®) 

Solid Biopsy (OncoDEEP®)Liquid Biopsy (OncoSELECT®)Cancer Monitoring (OncoFOLLOW®)Molecular Residual Disease (MRD) 

About UsCertifications & AccreditationsTeamAwardsCareersIntegraGen subsidiary investors

Precision medicine solutions for healthcare institutions, pharmaceutical companies and academic researchers 

	A unique dedicated portal with high-value scientific materials and major updates in the field of oncology, genetics and precision medicine.	

 Case of the Month
March: 42-year-old male with a metastatic colorectal cancer

Here we will describe the case of a man of 42 years old diagnosed in 221 with metastatic colorectal cancer. 

 Gridbuilder ᵂᴾ Plugin (https://wpgridbuilder.com) 

 Press Release
Leading European oncology center Gustave Roussy adopts OncoDNA’s OncoDEEP® Kit and automates library preparation and Target Enrichment using Bravo instrument.Feb 28th

Leading French and European comprehensive cancer center selects the OncoDEEP® Kit as the most complete solution with the highest number of relevant oncology biomarkers for use in its molecular laboratory.   Gosselies, Belgium and Paris,...Read more → Article
OncoDNA’s Evry laboratory atteins CLIA certification and CAP accreditation to reinforce its global clinical trial testing servicesFeb 23rd

In the ever-evolving landscape of oncology clinical trials, the pursuit of precision has become synonymous with progress. In this era where tailored therapies hold the promise of improved patient outcomes, the foundation of reliable and...Read more → Case of the Month
February: 4-year-old male with a stage IV glioma cancer2 min readingFeb 2th

OncoDEEP® identifies rare mutations & personalizes treatment for a 4-year-old male with a stage IV glioma cancerRead more → Webinar
Advancing personalized cancer treatment: Webinar ReplayFeb 19th

Webinar replay available now: Unlocking precision medicine through expert NGS panel design Discover the Future of Personalized Cancer Treatment Thank you for your interest in our groundbreaking webinar on the latest advancements in cancer research...Read more → Poster
Genome-wide circulating tumor DNA for monitoring treatment response and metastatic relapse in bladder cancer5 min readingJan 22nd

Introduction: The integration of neoadjuvant chemotherapy (NAC) followed by radical cystectomy (CX) marks a pivotal advancement in treating localized muscle-invasive bladder cancer (MIBC). Despite these efforts, approximately 45% of MIBC patients experience metastatic recurrence within...Read more →

 Webinar
Advancing personalized cancer treatment: explore the synergy of Twist Bioscience and OncoDNA in our webinarJan 22nd

Unlocking precision medicine through expert NGS panel design Tuesday, February 13, 20244:00 PM CEST By Dr. Marcel Trautmann, Koenraad Eycken, Dr. James Flynn Join our webinar to discover revolutionary insights into personalised cancer treatment with...Read more →

 Press Release
Revolutionary treatment for colorectal cancer: OncoDNA joins the PDC*neo+ project for a personalised therapeutic vaccineJan 17th

Medical research is taking a quantum leap forward with the PDC*neo+ project, promising a significant progress in the treatment of colorectal cancer. Thanks to OncoDNA’s unique expertise in neoantigen identification and circulating tumour DNA (ctDNA)...Read more →

 Case of the Month
January: 45-year-old male with an intrahepatic cholangiocarcinoma2 min readingJan 16th

We will describe the case of a 45 year old man diagnosed with an intrahepatic cholangiocarcinoma in 2022. He was treated by surgery and had several cycle of chemotherapies. The patient shows signs of resistance...Read more → Poster
Whole genome cell-free tumor DNA mutational signatures for noninvasive monitoring of pediatric brain cancers5 min readingJan 8th

Overview: The technique of liquid biopsy represents a groundbreaking non-invasive method for tracking cancer progression and remission, particularly during treatment and follow-up phases. Despite its promise, the application of liquid biopsy in pediatric brain cancer...Read more → 

They trust us, we trust them 

Years of trust, countless tests run, genes, and trials explored. 

0

Of knowledge that matters

0

0

0

OncoDNA’s ultimate mission is to improve all patients’ health by empowering healthcare providers, biopharma companies and researchers to deliver the promise of precision medicine. In this relentless pursuit of better care, we have been building an ecosystem of partners involved along the entire value chain – from translational research and drug development to patient treatment, monitoring and reimbursement.  

Stay in the know​

Get the latest resources, news and more.	

monthly
NameThis field is for validation purposes and should be left unchanged.

OncoDNA is a theranostic and genomic company with renown expertise in precision oncology and genetic diseases. 

OncoDNA S.A. (headquarters)Rue Louis Breguet 1BE-6041 Gosselies

+32 (0) 71 18 35 00 

	©OncoDNA 2024. All rights reserved. VAT:BE0501631837	

	Made by Créatonit   Sitemap 

 Consent Management powered by Complianz | GDPR/CCPA Cookie Consent https://wordpress.org/plugins/complianz-gdpr 

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

The technical storage or access that is used exclusively for statistical purposes.
The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Manage {vendor_count} vendors
Read more about these purposes

Manage consent
 Start of Async HubSpot Analytics Code 

 End of Async HubSpot Analytics Code 

 This website is like a Rocket, isn't it? Performance optimized by WP Rocket. Learn more: https://wp-rocket.me - Debug: cached@1712130453